Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Karyopharm Therapeutics stock

KPTI
US48576U1060
A1W77U

Price

0.88
Today +/-
-0.00
Today %
-0.50 %
P

Karyopharm Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Karyopharm Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Karyopharm Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Karyopharm Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Karyopharm Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Karyopharm Therapeutics Stock Price History

DateKaryopharm Therapeutics Price
11/7/20240.88 undefined
11/6/20240.89 undefined
11/5/20240.85 undefined
11/4/20240.93 undefined
11/1/20240.90 undefined
10/31/20240.99 undefined
10/30/20240.84 undefined
10/29/20240.85 undefined
10/28/20240.90 undefined
10/25/20240.83 undefined
10/24/20240.82 undefined
10/23/20240.85 undefined
10/22/20240.85 undefined
10/21/20240.85 undefined
10/18/20240.87 undefined
10/17/20240.85 undefined
10/16/20240.85 undefined
10/15/20240.84 undefined
10/14/20240.85 undefined
10/11/20240.86 undefined
10/10/20240.85 undefined

Karyopharm Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Karyopharm Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Karyopharm Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Karyopharm Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Karyopharm Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Karyopharm Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Karyopharm Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Karyopharm Therapeutics’s growth potential.

Karyopharm Therapeutics Revenue, EBIT and net profit per share

DateKaryopharm Therapeutics RevenueKaryopharm Therapeutics EBITKaryopharm Therapeutics Net Income
2029e519.49 M undefined0 undefined50.87 M undefined
2028e406.68 M undefined47.93 M undefined5.09 M undefined
2027e343.93 M undefined-21.94 M undefined-3.5 M undefined
2026e206.12 M undefined-66.73 M undefined-57.44 M undefined
2025e169.15 M undefined-97.39 M undefined-90.48 M undefined
2024e155.78 M undefined-117.71 M undefined-85.12 M undefined
2023146.03 M undefined-129.54 M undefined-143.1 M undefined
2022157.1 M undefined-142.2 M undefined-165.3 M undefined
2021209.8 M undefined-98.3 M undefined-124.1 M undefined
2020108.1 M undefined-171.9 M undefined-196.3 M undefined
201940.9 M undefined-189.3 M undefined-199.6 M undefined
201830.3 M undefined-179.9 M undefined-178.4 M undefined
20171.6 M undefined-130.5 M undefined-129 M undefined
2016200,000 undefined-110.7 M undefined-109.6 M undefined
2015300,000 undefined-119.1 M undefined-118.2 M undefined
2014200,000 undefined-75.8 M undefined-75.8 M undefined
2013400,000 undefined-34 M undefined-33.9 M undefined
2012600,000 undefined-15.9 M undefined-15.9 M undefined
2011200,000 undefined-10.3 M undefined-10.3 M undefined

Karyopharm Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000013040108209157146155173208343406519
-------2,900.0033.33170.0093.52-24.88-7.016.1611.6120.2364.9018.3727.83
--------95.0097.2298.5696.1896.58------
0000000038105206151141000000
-10-15-34-75-119-110-130-179-189-171-98-142-129-117-97-66-21470
-------13,000.00-596.67-472.50-158.33-46.89-90.45-88.36-75.48-56.07-31.73-6.1211.58-
-10-15-33-75-118-109-129-178-199-196-124-165-143-84-85-53-3550
-50.00120.00127.2757.33-7.6318.3537.9811.80-1.51-36.7333.06-13.33-41.261.19-37.65-94.34-266.67900.00
27.627.66.131.135.637.545.956.8627275.281.9114.22000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Karyopharm Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Karyopharm Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
6.50.4156205.7175.6129.6146.5328.2262249.2228.6278191.44
000000007.912.922.547.126.96
0000000000000
000000000.32.64.14.23.04
0.40.62222.126.48.411.820.320.912.47
6.91158207.7177.6131.7148.5334.6278.6276.5275.5350.2233.92
0.30.30.22.83.52.82.23.913.711.69.67.44.88
0008.733.945.429.42224.2000
0000000000000
0000000000000
0000000000000
0001.20.50.50.30.70.70.720.10.61.64
0.30.30.212.737.948.731.96.616.436.529.786.52
7.21.3158.2220.4215.5180.4180.4341.2295313305.2358.2240.44
                         
10.818.300000000000.01
000.220.350.460.530.630.860.921.121.11.331.35
-12.7-28.6-62.6-138.3-256.5-366.1-495.3-673.7-873.3-1,069.6-1,178.6-1,343.9-1,487.04
7900-0.3-0.3-0.2-0.200.50.2-0.6-0.16
0000000000000
5.2-0.6154.9206.9198.4162.2129.5183.349.850.5-79.6-16.6-136.21
1.11.11.76.33.84.85.74.314.51.62.83.12
0.80.81.25.81111.421.432.542.554.871.461.364.7
0.20.10.40.20.30.422.410.12.80.90.71.81.65
0000000000000
0000000000000
2.123.312.315.116.649.546.946.360.273.765.969.48
0000000102.7183.4191302.3302.8303.4
0000000000000
0001.21.91.71.48.515.411.396.13.77
0001.21.91.71.4111.2198.8202.3311.3308.9307.17
2.123.313.51718.350.9158.1245.1262.5385374.8376.64
7.31.4158.2220.4215.4180.5180.4341.4294.9313305.4358.2240.44
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Karyopharm Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Karyopharm Therapeutics's financial health and stability.

Assets

Karyopharm Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Karyopharm Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Karyopharm Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Karyopharm Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-10-15-33-75-118-109-128-178-199-196-124-165-143
0000000000000
0000000000000
100940320-131-23-1931
01728354542353658697040
0000000000005
0000000000000
-8-15-30-51-94-84-73-159-190-160-107-149-92
000-2-100-200000
000-67-902417-10778-53141-1047
000-64-892417-10578-53142-1047
0000000000000
0000000166730000
11918511392517514950172131931
119185113925175316124172731931
00000000006000
0000000000000
3-6155-5-92-8194911-41108-60-83
-8.93-15.63-30.35-54.28-95.45-84.46-73.78-161.48-191.03-160.38-107.33-149.67-92.72
0000000000000

Karyopharm Therapeutics stock margins

The Karyopharm Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Karyopharm Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Karyopharm Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Karyopharm Therapeutics's sales revenue. A higher gross margin percentage indicates that the Karyopharm Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Karyopharm Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Karyopharm Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Karyopharm Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Karyopharm Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Karyopharm Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Karyopharm Therapeutics Margin History

Karyopharm Therapeutics Gross marginKaryopharm Therapeutics Profit marginKaryopharm Therapeutics EBIT marginKaryopharm Therapeutics Profit margin
2029e96.62 %0 %9.79 %
2028e96.62 %11.78 %1.25 %
2027e96.62 %-6.38 %-1.02 %
2026e96.62 %-32.37 %-27.87 %
2025e96.62 %-57.58 %-53.49 %
2024e96.62 %-75.56 %-54.64 %
202396.62 %-88.71 %-97.99 %
202296.69 %-90.52 %-105.22 %
202198.38 %-46.85 %-59.15 %
202097.5 %-159.02 %-181.59 %
201994.13 %-462.84 %-488.02 %
201896.62 %-593.73 %-588.78 %
201796.62 %-8,156.25 %-8,062.5 %
201696.62 %-55,350 %-54,800 %
201596.62 %-39,700 %-39,400 %
201496.62 %-37,900 %-37,900 %
201396.62 %-8,500 %-8,475 %
201296.62 %-2,650 %-2,650 %
201196.62 %-5,150 %-5,150 %

Karyopharm Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Karyopharm Therapeutics earnings per share therefore indicates how much revenue Karyopharm Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Karyopharm Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Karyopharm Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Karyopharm Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Karyopharm Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Karyopharm Therapeutics Revenue, EBIT and net profit per share

DateKaryopharm Therapeutics Sales per ShareKaryopharm Therapeutics EBIT per shareKaryopharm Therapeutics Earnings per Share
2029e4.17 undefined0 undefined0.41 undefined
2028e3.26 undefined0 undefined0.04 undefined
2027e2.76 undefined0 undefined-0.03 undefined
2026e1.65 undefined0 undefined-0.46 undefined
2025e1.36 undefined0 undefined-0.73 undefined
2024e1.25 undefined0 undefined-0.68 undefined
20231.28 undefined-1.13 undefined-1.25 undefined
20221.92 undefined-1.74 undefined-2.02 undefined
20212.79 undefined-1.31 undefined-1.65 undefined
20201.5 undefined-2.39 undefined-2.73 undefined
20190.66 undefined-3.05 undefined-3.22 undefined
20180.53 undefined-3.17 undefined-3.14 undefined
20170.03 undefined-2.84 undefined-2.81 undefined
20160.01 undefined-2.95 undefined-2.92 undefined
20150.01 undefined-3.35 undefined-3.32 undefined
20140.01 undefined-2.44 undefined-2.44 undefined
20130.07 undefined-5.57 undefined-5.56 undefined
20120.02 undefined-0.58 undefined-0.58 undefined
20110.01 undefined-0.37 undefined-0.37 undefined

Karyopharm Therapeutics business model

Karyopharm Therapeutics Inc. is a biopharmaceutical company based in Newton, Massachusetts. The company focuses its research and development on the use of selective inhibitors of nuclear export (SINE) for the treatment of cancer and inflammatory diseases. Karyopharm Therapeutics has been active in the field of biotechnology research since 2010. Karyopharm Therapeutics is one of the most popular companies on Eulerpool.com.

Karyopharm Therapeutics SWOT Analysis

Strengths

Karyopharm Therapeutics Inc. has a strong portfolio of proprietary drug candidates that target various forms of cancer, providing potential for significant revenue growth.

The company's core competency lies in the development and commercialization of novel treatments that harness the power of nuclear transport technology, which has the potential to revolutionize cancer therapeutics.

Karyopharm Therapeutics Inc. boasts a robust pipeline with multiple drugs in various stages of clinical development, indicating its commitment to innovation and expanding its product offerings.

Weaknesses

One weakness of Karyopharm Therapeutics Inc. is the potential dependence on the success of its drug candidates in clinical trials. Failure to achieve desired results could adversely impact the company's financial performance and reputation.

As a relatively small biopharmaceutical company, Karyopharm Therapeutics Inc. may face resource limitations, making it challenging to compete with larger, more established players in the industry.

Opportunities

The increasing prevalence of cancer worldwide presents a significant opportunity for Karyopharm Therapeutics Inc. to address unmet medical needs and capture a larger market share.

The company can explore strategic partnerships and collaborations with other pharmaceutical companies to leverage their expertise, access additional resources, and enhance its chances of success.

Expansion into international markets offers Karyopharm Therapeutics Inc. the potential to tap into a larger patient population, drive revenue growth, and diversify its geographical presence.

Threats

Karyopharm Therapeutics Inc. operates in a highly competitive industry, with numerous companies vying for market share and limited differentiation in some therapeutic areas. This poses a significant threat to the company's ability to capture and retain market share.

Changes in regulatory requirements and policies, both domestically and internationally, can impact the development, approval, and commercialization of Karyopharm Therapeutics Inc.'s drug candidates, potentially causing delays and additional expenses.

The biopharmaceutical industry is highly dependent on intellectual property rights. Any infringement on Karyopharm Therapeutics Inc.'s patents or unauthorized use of its proprietary technology could undermine its competitive advantage and expose the company to legal challenges.

Karyopharm Therapeutics Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Karyopharm Therapeutics Revenue by Segment

Segmente2022202120202019
Product120.45 M USD---
License and Other36.63 M USD---

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Karyopharm Therapeutics Revenue by Segment

Segmente2022202120202019
License and other revenue----

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Karyopharm Therapeutics Revenue by Segment

Segmente2022202120202019
Product-98.44 M USD76.21 M USD30.54 M USD
License And Other Revenue-111.38 M USD--
License And Other--31.88 M USD10.35 M USD

Karyopharm Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Karyopharm Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Karyopharm Therapeutics shares outstanding

The number of shares was Karyopharm Therapeutics in 2023 — This indicates how many shares 114.221 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Karyopharm Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Karyopharm Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Karyopharm Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Karyopharm Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Karyopharm Therapeutics.

Karyopharm Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.27 -0.26  (3.02 %)2024 Q3
6/30/2024-0.3 0.15  (149.26 %)2024 Q2
3/31/2024-0.34 -0.32  (6.02 %)2024 Q1
12/31/2023-0.32 -0.36  (-13.96 %)2023 Q4
9/30/2023-0.29 -0.3  (-5.04 %)2023 Q3
6/30/2023-0.35 -0.29  (16.93 %)2023 Q2
3/31/2023-0.38 -0.3  (20.13 %)2023 Q1
12/31/2022-0.36 -0.43  (-19.41 %)2022 Q4
9/30/2022-0.58 -0.45  (22 %)2022 Q3
6/30/2022-0.65 -0.62  (4.02 %)2022 Q2
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Karyopharm Therapeutics stock

Eulerpool World ESG Rating (EESG©)

56/ 100

🌱 Environment

58

👫 Social

99

🏛️ Governance

11

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees57
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Karyopharm Therapeutics shareholders

%
Name
Stocks
Change
Date
6.13930 % The Vanguard Group, Inc.7,654,482-683,9196/30/2024
5.51173 % J. Wood Capital Advisors LLC6,872,0276,872,0275/13/2024
4.09223 % Palo Alto Investors LP5,102,19306/30/2024
3.99998 % Eversept Partners, LP4,987,180-29,1406/30/2024
3.46474 % Adage Capital Management, L.P.4,319,842819,8426/30/2024
2.62983 % BlackRock Institutional Trust Company, N.A.3,278,878-4,565,7096/30/2024
2.48749 % Citadel Advisors LLC3,101,399-3,6706/30/2024
2.06999 % Marshall Wace LLP2,580,863-14,7366/30/2024
1.82403 % BNP Paribas Securities Corp. North America2,274,195500,4376/30/2024
1.77021 % Goldman Sachs & Company, Inc.2,207,092766,8596/30/2024
1
2
3
4
5
...
10

Karyopharm Therapeutics Executives and Management Board

Mr. Richard Paulson(55)
Karyopharm Therapeutics President, Chief Executive Officer, Director (since 2020)
Compensation 6.91 M
Mr. Michael Mason(48)
Karyopharm Therapeutics Chief Financial Officer, Executive Vice President, Treasurer
Compensation 2.7 M
Ms. Sohanya Cheng(40)
Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer
Compensation 2.61 M
Mr. Michael Mano(46)
Karyopharm Therapeutics Senior Vice President, General Counsel, Secretary
Compensation 2.06 M
Mr. Stuart Poulton
Karyopharm Therapeutics Executive Vice President, Chief Development Officer
Compensation 1.78 M
1
2
3

Karyopharm Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Antengene Corp Rg Stock
Antengene Corp Rg
SupplierCustomer0,75-0,150,38-0,140,12
SailPoint Technologies Stock
SailPoint Technologies
SupplierCustomer0,680,80-0,21-0,57-0,16-0,29
Veeva Systems A Stock
Veeva Systems A
SupplierCustomer-0,030,800,810,320,020,12
Smartsheet-A Rg Stock
Smartsheet-A Rg
SupplierCustomer-0,390,780,830,210,04-0,23
1

Most common questions regarding Karyopharm Therapeutics

What values and corporate philosophy does Karyopharm Therapeutics represent?

Karyopharm Therapeutics Inc represents a values-driven corporate philosophy centered on innovative therapies for patients. The company is committed to developing novel treatments to address unmet medical needs and improve the lives of individuals, guided by the principles of integrity, collaboration, and perseverance. Karyopharm Therapeutics Inc places a strong emphasis on scientific research and breakthrough discoveries to deliver potential breakthrough therapies in oncology and other diseases. With a focus on patient-centricity, they aim to advance transformative medicines that can make a significant impact on healthcare. Karyopharm Therapeutics Inc's dedication to driving medical innovation and improving patient outcomes underscores their commitment to excellence.

In which countries and regions is Karyopharm Therapeutics primarily present?

Karyopharm Therapeutics Inc is primarily present in the United States (US).

What significant milestones has the company Karyopharm Therapeutics achieved?

Karyopharm Therapeutics Inc. has achieved several significant milestones since its establishment. Firstly, the company received FDA approval for its first commercial product XPOVIO (selinexor) in July 2019. This marked a major accomplishment as XPOVIO became the first oral Selective Inhibitor of Nuclear Export (SINE) compound to receive regulatory approval. Moreover, Karyopharm Therapeutics Inc. has successfully expanded its product portfolio, with ongoing research and development programs focusing on potential treatments for various forms of cancer. The company continues to actively engage in clinical trials and collaborations, aiming to further enhance its position as an innovative leader in the biopharmaceutical industry.

What is the history and background of the company Karyopharm Therapeutics?

Karyopharm Therapeutics Inc. is a renowned pharmaceutical company focused on the development of novel therapies for the treatment of cancer and other diseases. Established in 2008, Karyopharm has grown into a leading biopharmaceutical firm dedicated to discovering innovative solutions for patients in need. With a proven track record in research and development, the company has successfully advanced numerous clinical-stage drug candidates, including its flagship product, XPOVIO® (selinexor). Karyopharm's mission revolves around improving patient outcomes and quality of life through effective and targeted therapies. Through its dedication to scientific advancement and commitment to patients, Karyopharm Therapeutics Inc. has become a prominent player in the pharmaceutical industry.

Who are the main competitors of Karyopharm Therapeutics in the market?

The main competitors of Karyopharm Therapeutics Inc in the market include large pharmaceutical companies such as Novartis, Pfizer, and GlaxoSmithKline. These companies also operate in the biotechnology and pharmaceutical sectors, offering a range of products and services similar to Karyopharm Therapeutics Inc. In addition, there are smaller biotech companies like Celgene and Gilead Sciences that may have overlapping areas of focus and compete with Karyopharm Therapeutics Inc.

In which industries is Karyopharm Therapeutics primarily active?

Karyopharm Therapeutics Inc is primarily active in the biopharmaceutical industry.

What is the business model of Karyopharm Therapeutics?

The business model of Karyopharm Therapeutics Inc. revolves around the development and commercialization of novel drugs for the treatment of cancer and other diseases. With a focus on targeting nuclear transport and related signaling pathways, Karyopharm Therapeutics aims to deliver innovative therapies that address unmet medical needs. By leveraging its expertise in drug discovery and development, the company strives to bring effective and safe treatments to patients worldwide. Karyopharm Therapeutics Inc. combines scientific advancements with strategic partnerships and collaborations to accelerate the development and commercial success of its drug candidates, ultimately improving the lives of patients in need.

What is the P/E ratio of Karyopharm Therapeutics 2024?

The Karyopharm Therapeutics P/E ratio is -1.18.

What is the P/S ratio of Karyopharm Therapeutics 2024?

The Karyopharm Therapeutics P/S ratio is 0.65.

What is the Quality Investing of Karyopharm Therapeutics?

The Quality Investing for Karyopharm Therapeutics is 6/10.

What is the revenue of Karyopharm Therapeutics 2024?

The expected Karyopharm Therapeutics revenue is 155.78 M USD.

How high is the profit of Karyopharm Therapeutics 2024?

The expected Karyopharm Therapeutics profit is -85.12 M USD.

What is the business model of Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of therapies for the treatment of cancer and other serious diseases. The company operates in various business areas, including research and development, manufacturing and distribution of drugs, and clinical trials. The research and development department of Karyopharm aims to develop innovative therapies based on the principle of selective inhibition of nuclear transport proteins (NTPs). These proteins play a crucial role in the regulation of gene expression and cell growth, making them a promising target for cancer therapy. The company has an extensive portfolio of NTP inhibitors, including XPOVIO (Selinexor), an orally administered therapy for the treatment of patients with recurrent or refractory multiple myeloma. Karyopharm's production department is responsible for manufacturing drugs in commercial quantities. The company has several production facilities that meet the highest quality standards and are approved by the US Food and Drug Administration (FDA). Medications are produced here and then distributed worldwide. The distribution of Karyopharm's products is done through a network of distributors and partner companies in the US and other countries worldwide. With its strong focus on research and development, drug production, and distribution, Karyopharm Therapeutics has become a key player in the cancer therapy market. Karyopharm's portfolio includes a variety of groundbreaking products that aim to improve the treatment of cancer and other serious diseases in innovative ways. One outstanding product in this area is XPOVIO (Selinexor), which was approved by the FDA in 2019. XPOVIO is an orally administered drug indicated for the treatment of patients with recurrent or refractory multiple myeloma. The medication has shown significant efficacy in several clinical trials and is considered a major breakthrough in cancer treatment by experts. Overall, Karyopharm's business model is focused on developing and marketing innovative therapies for the treatment of cancer and other serious diseases worldwide. With its strong emphasis on research and development, drug production and distribution, and clinical trials, Karyopharm has made a name for itself in the industry and is poised to continue playing an important role in the future.

What is the Karyopharm Therapeutics dividend?

Karyopharm Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Karyopharm Therapeutics pay dividends?

The dividend cannot currently be calculated for Karyopharm Therapeutics or the company does not pay out a dividend.

What is the Karyopharm Therapeutics ISIN?

The ISIN of Karyopharm Therapeutics is US48576U1060.

What is the Karyopharm Therapeutics WKN?

The WKN of Karyopharm Therapeutics is A1W77U.

What is the Karyopharm Therapeutics ticker?

The ticker of Karyopharm Therapeutics is KPTI.

How much dividend does Karyopharm Therapeutics pay?

Over the past 12 months, Karyopharm Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Karyopharm Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Karyopharm Therapeutics?

The current dividend yield of Karyopharm Therapeutics is .

When does Karyopharm Therapeutics pay dividends?

Karyopharm Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Karyopharm Therapeutics?

Karyopharm Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Karyopharm Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Karyopharm Therapeutics located?

Karyopharm Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Karyopharm Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Karyopharm Therapeutics from 11/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.

When did Karyopharm Therapeutics pay the last dividend?

The last dividend was paid out on 11/8/2024.

What was the dividend of Karyopharm Therapeutics in the year 2023?

In the year 2023, Karyopharm Therapeutics distributed 0 USD as dividends.

In which currency does Karyopharm Therapeutics pay out the dividend?

The dividends of Karyopharm Therapeutics are distributed in USD.

All fundamentals about Karyopharm Therapeutics

Our stock analysis for Karyopharm Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karyopharm Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.